New Clinical Trial Evaluates Speech Therapy for Rare Neurodegenerative Disorder
A groundbreaking clinical trial explores innovative speech therapy approaches for patients with the rare and progressive neurological disorder MSA-C, highlighting promising results from telehealth models that improve communication and quality of life.
Researchers at the University of Strathclyde in Glasgow have conducted the largest clinical study to date assessing speech therapy techniques for individuals suffering from a rare, rapidly progressing, and fatal neurological condition known as cerebellar variant of Muscular System Atrophy (MSA-C). The study compared two approaches: traditional speech therapy and a novel telehealth model called ClearSpeechTogether, developed specifically at the University.
The randomized controlled trial involved participants undergoing 24 therapy sessions over six weeks. The treatments aimed to enhance communication skills, with findings indicating improvements in communication confidence and participation in both groups. Notably, preliminary results suggest that ClearSpeechTogether may offer greater benefits, especially for individuals at more advanced stages of MSA-C.
MSA-C severely impacts balance, movement, and speech, often leading to early communication difficulties that diminish quality of life and social interactions. The innovative telehealth-based model combines individual therapy sessions with peer-led online group meetings, making intensive treatment accessible and sustainable despite the degenerative nature of the disease.
Participants appreciated the social support and empowerment gained through the group therapy format, with some continuing independent practice beyond the study period. The research, published in The Cerebellum, underscores the potential of accessible, high-quality speech therapy options to improve life quality for those affected by neurodegenerative conditions.
According to lead author Professor Anja Lowit, the study demonstrates that even individuals with advanced stages of MSA-C can participate fully and experience meaningful improvements. She emphasizes that ClearSpeechTogether could be a cost-effective and practical tool to help maintain speech and social connection longer. Renowned neurologist Professor Marios Hadjivassiliou also highlighted the importance of developing effective treatment strategies for this currently untreatable disease.
This pioneering research opens avenues for larger clinical trials and the broader application of telehealth-based speech therapy in neurodegenerative diseases, offering hope for improved patient outcomes in the future.
Source: https://medicalxpress.com/news/2025-08-clinical-trial-speech-therapy-rare.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Promising Results for Novel Antibody-Drug Conjugate in EGFR-Mutated Non-Small Cell Lung Cancer
A new antibody-drug conjugate shows promising safety and efficacy in treating EGFR-mutated non-small cell lung cancer, offering hope for targeted therapy advancements.
New Immune Cell Population Could Transform Tuberculosis Vaccine Development
Researchers at Stony Brook University have identified a novel immune cell type, expressing CD8a on NK cells, that may open new pathways for TB vaccine development and immune therapy, potentially transforming tuberculosis control strategies.
Concerns Arise Over Long-Term Safety of ADHD Medication in Children
Recent research raises concerns about the safety of long-term ADHD medication use in children, emphasizing the need for cautious prescribing and more comprehensive safety studies.
The Overlooked Role of Weight-Loss Behaviors in Diagnosing Eating Disorders
A recent study reveals significant gaps in current eating disorder assessments, highlighting the need to include a broader range of weight-loss behaviors for accurate diagnosis and personalized treatment.